GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy

被引：0

作者：

Liu, Yanfeng ^{[1
,2
,3
]}

Liu, Yi ^{[2
,3
]}

Chen, Peng ^{[1
,4
]}

Chen, Ge ^{[1
,4
]}

Chen, Xiaoping ^{[1
,3
,4
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha 410008, Peoples R China

[3] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China

[4] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Peoples R China

来源：

ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 06期

关键词：

Cytarabine; Acute myeloid leukemia; Glioma-associated oncogene homolog 1; Hedgehog; Single nucleotide polymorphisms; INHIBITION; EXPRESSION; CELLS; CD44;

D O I：

10.1007/s00277-024-05777-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy. Cytarabine (Ara-C)-based chemotherapy is the primary treatment for AML, but currently known prognostic risk stratification factors cannot fully explain the individual differences in outcome of patients. In this article, we reported that patients with homozygous GLI1 rs2228224 mutation (AA genotype) had a significantly lower complete remission rate than those with GG wild type (54.17% vs.76.02%, OR = 1.993, 95% CI: 1.062-3.504, P = 0.031). GLI1 rs2229300 T allele carriers had remarkably shorter overall survival (513 vs. 645 days, P = 0.004) and disease-free survival (342 vs. 456 days, P = 0.033) than rs2229300 GG carriers. Rs2229300 G > T variation increased the transcriptional activity of GLI1. CCND1, CD44 and PROM1 were potential target genes differentially regulated by GLI1 rs2229300. Our results demonstrated for the first time that GLI1 polymorphisms influence chemosensitivity and prognosis of young de novo AML patients treated with Ara-C.

引用

页码：1967 / 1977

页数：11